RxDoctor Payments Data

Marcy Oppenheimer, MD

Family Medicine · Washington, DCNPI 1023243581

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 27.2% of the total.

$322in general payments, 2019–2025

Across 19 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$88
  • Amgen$55
  • AstraZeneca$48
  • Lilly USA, LLC$41
  • AbbVie$24
  • Novartis$23
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$322100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$322 in reported general payments places this provider in the 70th percentile of 166 family medicine providers in District of Columbia.

See all family medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$64,494
Medicare patients
112
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide85$132,035
JardianceEmpagliflozin33$45,576
OzempicSemaglutide28$35,952
EliquisApixaban24$30,808
CreonLipase/Protease/Amylase12$28,538
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$20,120
TradjentaLinagliptin18$15,235
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,684
Atorvastatin Calcium351$2,578
Gabapentin91$2,220
Albuterol Sulfate HfaAlbuterol Sulfate80$2,082
Amlodipine Besylate291$1,896
Wixela InhubFluticasone Propion/Salmeterol13$1,822
Colchicine25$1,813
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$41$132,03585 claims
Novo NordiskOzempic$22$35,95228 claims
PfizerEliquis$22$30,80824 claims
AbbVieCreon$24$28,53812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 family medicine providers in District of Columbia.

Other family medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →